ResMed

Sleep Aids Technologies and Global Markets Report 2023-2027: Revolutionizing Rest - Latest Trends, Opportunities, and Leading Sleep Aids Players - ResearchAndMarkets.com

Retrieved on: 
星期一, 九月 4, 2023
Health Technology, Health, Medical Devices, ResMed, Prevalence, Boehringer Ingelheim, Health care, Sleep, Cancer, Pfizer, Sleep apnea, Organization, Insomnia, Developed country, Fisher & Paykel Healthcare, AMI, Conditional sentence, Environment, Pharmaceutical industry, Renewable energy, Marketing

The "Sleep Aids: Technologies and Global Markets" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Sleep Aids: Technologies and Global Markets" report has been added to ResearchAndMarkets.com's offering.
  • This report examines the way in which the sleep aids market is changing and how it has evolved.
  • This report highlights the current and future market potential for sleep aids and provides a detailed analysis of the competitive environment, regulatory scenario, drivers, restraints, opportunities and trends in the market.
  • Medication, sleep laboratories, sleep apnea devices, and mattresses and pillows are all examples of sleep aids.

ResMed Inc. Announces Results for the Fourth Quarter of Fiscal Year 2023

Retrieved on: 
星期四, 八月 3, 2023
Abstract, Software as a service, CDI, Heart failure, CSA, CHESS, Sleep, Quality of life, OSA, ResMed, Australian Securities Exchange, Trial of the century, American Thoracic Society, Acquisition, Patient, Physician, ASV, PAP, Webcast, Mortality, NYSE, Lennoxville (Airview) Airport, Cryptocurrency, Video game, Pharmaceutical industry, Security (finance)

SAN DIEGO, Aug. 03, 2023 (GLOBE NEWSWIRE) -- ResMed Inc. (NYSE: RMD, ASX: RMD) today announced results for its quarter ended June 30, 2023.

Key Points: 
  • Revenue in the U.S., Canada, and Latin America, excluding Software-as-a-Service, grew by 25 percent, primarily due to the factors discussed above.
  • SG&A expenses increased to 21.5 percent of revenue in the quarter, compared with 21.1 percent in the same period of the prior year.
  • ResMed has received a waiver from the ASX’s settlement operating rules, which will allow ResMed to defer processing conversions between its common stock and CDI registers from August 16, 2023, through August 17, 2023, inclusive.
  • ResMed will discuss its fourth-quarter fiscal year 2023 results on its webcast at 1:30 p.m. U.S. Pacific Time today.

Publication Relating to a Transparency Notification

Retrieved on: 
星期四, 七月 27, 2023
Person, Mercury – Acts 1 & 2, Disclosure, ResMed, Euronext, Mont-Saint-Guibert, CET

Mont-Saint-Guibert (Belgium), July 27, 2023, 10.30pm CET / 4.30pm ET – In accordance with article 14 of the Act of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) announces that it received a rectification of an earlier transparency notification.

Key Points: 
  • Mont-Saint-Guibert (Belgium), July 27, 2023, 10.30pm CET / 4.30pm ET – In accordance with article 14 of the Act of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) announces that it received a rectification of an earlier transparency notification.
  • On July 25, 2023, Nyxoah received the rectification of the April 16, 2023 transparency notification that it had received from ResMed Inc. in relation to the upward crossing of the 5% threshold by ResMed Inc. on March 30, 2023.
  • The correction relates to the number of shares and the percentage of voting rights held by ResMed Inc. on March 30, 2023: ResMed Inc. held 1,619,756 shares, representing 5.73% of the total number of voting rights (and not 1,499,756 shares or 5.30% of the voting rights as stated in the April 2023 notification).
  • The notification dated July 17, 2023 contains the following information:
    Persons subject to the notification requirement: ResMed Inc., 9001 Spectrum Center Boulevard, San Diego, CA 92123, USA
    Date on which the threshold was crossed: March 30, 2023

CerraCap Ventures Celebrates Successful Exit as ResMed Acquires Portfolio Company Somnoware Healthcare Systems Inc.

Retrieved on: 
星期三, 七月 19, 2023
Sleep, Growth, Philosophy, Acquisition, Marketing, Physician, ResMed, Pharmaceutical industry, Nursing

COSTA MESA, Calif., July 19, 2023 /PRNewswire/ -- CerraCap Ventures, a leading venture capital firm specializing in early-stage investments, is excited to announce the successful exit of their fund's portfolio company, Somnoware Healthcare Systems Inc., through its acquisition by ResMed, a global leader in sleep and respiratory care. This significant milestone marks a new chapter in Somnoware's journey as it continues to accelerate its expansion in sleep, respiratory care, and additional healthcare markets.

Key Points: 
  • COSTA MESA, Calif., July 19, 2023 /PRNewswire/ -- CerraCap Ventures, a leading venture capital firm specializing in early-stage investments, is excited to announce the successful exit of their fund's portfolio company, Somnoware Healthcare Systems Inc., through its acquisition by ResMed, a global leader in sleep and respiratory care.
  • Under the strategic guidance and support of CerraCap Ventures, Somnoware has experienced remarkable growth and expanded its footprint in the respiratory healthcare space.
  • "We are thrilled to announce the successful exit and acknowledge the crucial role played by CerraCap Ventures in accelerating our growth and expanding our presence in the respiratory healthcare sector," said Subath Kamalasan, CEO of Somnoware.
  • "We take great pride in being part of Somnoware's journey and extend our congratulations on their successful exit," said Saurabh Ranjan, Founder & CEO of CerraCap Ventures.

Omnicell Appoints Bobby Ghoshal to Board of Directors

Retrieved on: 
星期二, 七月 11, 2023
Data Management, Health, Technology, Hospitals, Practice Management, Software, Pharmaceutical, Semiconductor, Software as a service, OMCL, Autonomous pharmacy, Multimedia, ResMed, Machine learning, Artificial intelligence, Management, Omnicell

Omnicell, Inc. (NASDAQ:OMCL) (“Omnicell” or the “Company”), a leader in transforming the pharmacy care delivery model, today announced it has increased its number of board seats from 9 to 10, and has appointed Kaushik “Bobby” Ghoshal to fill the newest seat as an independent director of Omnicell’s Board of Directors, effective immediately.

Key Points: 
  • Omnicell, Inc. (NASDAQ:OMCL) (“Omnicell” or the “Company”), a leader in transforming the pharmacy care delivery model, today announced it has increased its number of board seats from 9 to 10, and has appointed Kaushik “Bobby” Ghoshal to fill the newest seat as an independent director of Omnicell’s Board of Directors, effective immediately.
  • View the full release here: https://www.businesswire.com/news/home/20230711576271/en/
    Omnicell Appoints Bobby Ghoshal to Board of Directors (Photo: Business Wire)
    Mr. Ghoshal is an established technology leader who brings more than 30 years of experience across multiple industries including finance, semiconductors, and healthcare.
  • “We are delighted to welcome Bobby to Omnicell’s Board of Directors,” said Randall Lipps, chairman, president, chief executive officer, and founder of Omnicell.
  • The Board now comprises 10 directors, 9 of whom are independent and all of whom bring a broad range of skills and experience that enhance the Board’s ability to effectively fulfill its governance and oversight responsibilities.

ResMed to Report Fourth Quarter Fiscal 2023 Earnings on August 3, 2023

Retrieved on: 
星期四, 七月 6, 2023
ResMed, Webcast, Online shopping, Broadcasting

Please note, ResMed does not use outside phone lines to access the earnings call, the call is accessible via the above webcast link only.

Key Points: 
  • Please note, ResMed does not use outside phone lines to access the earnings call, the call is accessible via the above webcast link only.
  • A replay of the earnings webcast will be accessible on ResMed’s website and available approximately two hours after the webcast.
  • In addition, a phone replay will be available approximately three hours after the webcast and will be accessible from August 3, 2023, until August 17, 2023, at:

ResMed Acquires Somnoware, a Leader in Digital Sleep and Respiratory Care Diagnostics Software

Retrieved on: 
星期三, 七月 5, 2023
King & Spalding, COPD, Acute HME syndrome, Partnership, Sleep, RMD, ASX, OSA, ResMed, Acquisition, Patient, Physician, SAN, PAP, Diagnosis, Ecosystem, Health, Piper, DLA Piper, NYSE, Nursing

“We are thrilled to welcome the Somnoware team to ResMed,” said ResMed Sleep & Respiratory Care President Lucile Blaise.

Key Points: 
  • “We are thrilled to welcome the Somnoware team to ResMed,” said ResMed Sleep & Respiratory Care President Lucile Blaise.
  • Improving patients’ experience and health outcomes is our common goal.”
    “We are very excited about this acquisition,” said ResMed North America General Manager Bill Shoop.
  • “Somnoware’s offering has been well received in the marketplace and it naturally complements our ecosystem of digital solutions across the patient care pathway.
  • Our partnership will open new avenues to help physicians with the critical task of chronic care management,” said Subath Kamalasan, Somnoware cofounder and CEO.

HLTH Is Coming: Preeminent Health Innovation Event In The U.S. Launches In Europe & Announces First Supporters

Retrieved on: 
星期一, 六月 19, 2023
Guy's and St Thomas' NHS Foundation Trust, Health, Policy, Headspace, RAI Amsterdam, ResMed, Withings, Sheba Medical Center, NHS foundation trust, Novo Nordisk, AWS, Content, AptarGroup, Shop Talk

HLTH (pronounced "health") has quickly established itself as the definitive healthcare event in the US.

Key Points: 
  • HLTH (pronounced "health") has quickly established itself as the definitive healthcare event in the US.
  • Founded by serial entrepreneur and investor, Jonathan Weiner, HLTH will be the third event he has founded to be brought to Europe at scale.
  • HLTH Europe's agenda will profile the individuals and organisations catalysing action and inspiring change across the entire European health ecosystem.
  • HLTH Europe will focus on tackling the difficult conversations and exploring the many opportunities in European health today,' said Lina Behrens, Head of Content, HLTH Europe.

HLTH Is Coming: Preeminent Health Innovation Event In The U.S. Launches In Europe & Announces First Supporters

Retrieved on: 
星期一, 六月 19, 2023
Guy's and St Thomas' NHS Foundation Trust, Health, Policy, Headspace, RAI Amsterdam, ResMed, Withings, Sheba Medical Center, NHS foundation trust, Novo Nordisk, AWS, Content, AptarGroup, Shop Talk

HLTH (pronounced "health") has quickly established itself as the definitive healthcare event in the US.

Key Points: 
  • HLTH (pronounced "health") has quickly established itself as the definitive healthcare event in the US.
  • Founded by serial entrepreneur and investor, Jonathan Weiner, HLTH will be the third event he has founded to be brought to Europe at scale.
  • HLTH Europe's agenda will profile the individuals and organisations catalysing action and inspiring change across the entire European health ecosystem.
  • HLTH Europe will focus on tackling the difficult conversations and exploring the many opportunities in European health today,' said Lina Behrens, Head of Content, HLTH Europe.

Generational Equity Advises Red Oak Medical Supply in Its Sale to Private Investor

Retrieved on: 
星期四, 六月 15, 2023
Medical Supplies, Finance, Hospitals, Banking, Business, Professional Services, Small Business, Practice Management, Health, Institute for Private Investors, Central Region, ROMS, Senior, Jobst, Equity, Innogen, MEDLINE, Hollister, Sale, M&A, Nova, Pleasure, Convatec, Bariatrics, Nursing, Respironics, ResMed, Invacare

Generational Equity , a leading mergers and acquisitions advisor for privately held businesses, is pleased to announce the sale of its client Emaan Medical Supply, Inc. (dba, Red Oak Medical Supply) to a Private Investor.

Key Points: 
  • Generational Equity , a leading mergers and acquisitions advisor for privately held businesses, is pleased to announce the sale of its client Emaan Medical Supply, Inc. (dba, Red Oak Medical Supply) to a Private Investor.
  • Founded in 1997, Red Oak Medical Supply (ROMS), located in Houston, Texas, is one of the leading medical supply retailers in Houston.
  • With more than 10,000 unique items in stock, ROMS is truly a one-stop-shop for all medical supplies in Houston.
  • "It was a pleasure working with the seller and buyer as both have similar values,” said Farahmandi.